SEC Form 4 · accession 0001415889-15-000153

ACADIA PHARMACEUTICALS INC · ACAD

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Jan 13, 2015

Accepted (ET)

Jan 15, 2015 · 6:03 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001070494

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Jan 13, 2015	M	4,685	$15.02	A	13,185	I	See footnote
Common Stock^F1	Jan 13, 2015	M	7,220	$8.49	A	20,405	I	See footnote
Common Stock^F3,F1	Jan 13, 2015	S	11,905	$35.0001	D	8,500	I	See footnote

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock option (right to buy)^F1,F4	$15.02	Jan 13, 2015	M	4,685	D	—	Jun 14, 2017	Common Stock	4,685	0	I
Stock option (right to buy)^F1,F5	$8.49	Jan 13, 2015	M	7,220	D	—	Jun 12, 2018	Common Stock	7,220	2,780	I

F1Shares and options are held by Morgan Management Aps, a Danish corporation in which Mr. Rasmussen has a controlling interest.
F2The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2014.
F3The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.01 per share, inclusive. The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range.
F425% of the shares subject to the stock option vested and became exercisable at the end of each 3-month period following the date of grant of June 15, 2007.
F525% of the share subject to the stock option vested and became exercisable at the end of each 3-month period following the date of grant of June 13, 2008.